10-Hydroxycamptothecin
(S) -10-Hydroxycamptothecin is a clinical therapy agent against hepatoma. (In Vitro) : (S) -10-Hydroxycamptothecin (5-20 μg/L; 6 days; Hep G2 cells) treatment results in the cell cycle arrest at G2/M phase. (S) -10-Hydroxycamptothecin induces differentiation, down-regulates nuclear antigen (PCNA) and up-regulates wild-type protein p53 in Hep G2 cells. (S) -10-Hydroxycamptothecin inhibits L1210 leukemia cells with an IC50 of 1.15 μM. (In Vivo) : (S) -10-Hydroxycamptothecin (10-Hydroxycamptothecin) against L1210 leukemia in mice is tested. At the optimal dose (15 mg/kg), (S) -10-Hydroxycamptothecin has a 71% increase in life span (ILS) .
Product Specifications
CAS Number
19685-09-7
Product Name Alternative
ChEMBL 273862 | NSC 107124
Purity
>98% (HPLC)
Solubility
DMSO: 8 mg/mL warmed (21.95 mM)
Smiles
O=C1[C@] (O) (CC) C2=C (CO1) C (N3CC4=CC5=CC (O) =CC=C5N=C4C3=C2) =O
Molecular Formula
C20H16N2O5
Molecular Weight
364.36
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
(S) -4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14 (4H,12H) -dione
Available Sizes
Explore Other Products
Browse additional items from our catalog